{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:45:48Z","timestamp":1768481148377,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Reviva Pharmaceuticals, Inc","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13318-018-0472-z","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T06:48:18Z","timestamp":1522824498000},"page":"573-585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder"],"prefix":"10.1007","volume":"43","author":[{"given":"Marc","family":"Cantillon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arul","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0503-8537","authenticated-orcid":false,"given":"Laxminarayan","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"issue":"9690","key":"472_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J Os van","year":"2009","unstructured":"van Os J, Kapur S. Schizophr Lancet. 2009;374(9690):635\u201345.","journal-title":"Schizophr Lancet"},{"key":"472_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Schizophrenia and other psychotic disorders. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association; 2013. p. 89\u2013122.","edition":"5"},{"key":"472_CR3","unstructured":"National Institute of Mental Health. Schizophrenia. 2009. Available at: http:\/\/www.nimh.nih.gov\/health\/publications\/schizophrenia-easyto-read\/nimh-schizophrenia-quadfold.pdf . Accessed 20 June 2014."},{"key":"472_CR4","unstructured":") National Institute of Mental Health. What is Schizophrenia? 2015. http:\/\/www.nimh.nih.gov\/health\/topics\/schizophrenia\/index.shtml . Accessed 4 June 2017."},{"key":"472_CR5","unstructured":"Opler L, Kay S, Lindenmayer JP, et al. Structured clinical interview\u2014positive and negative syndrome scale. North Tonawanda: Multi-Health Systems; 1999. https:\/\/www.mhs.com\/MHS-Assessment?prodname=panss . Accessed 4 June 2017."},{"key":"472_CR6","unstructured":"The American College of Neuropsychopharmacology (ACNP). Neuropsychopharmacology-5th Generation of Progress (2010) Section\u00a06, Schizophrenia. Available at: http:\/\/www.acnp.org\/publications\/neuro5thgeneration.aspx . Accessed 4 June 2017."},{"key":"472_CR7","doi-asserted-by":"crossref","unstructured":"Meltzer HY, Risinger R, Nasrallah HA. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015;76(8):1085\u201390.","DOI":"10.4088\/JCP.14m09741"},{"key":"472_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1192\/apt.9.3.202","volume":"9","author":"D Baldwin","year":"2003","unstructured":"Baldwin D, Mayers A. Sexual side-effects of antidepressant and antipsychotic drugs. Adv Psychiatry Ther. 2003;9:202\u201310.","journal-title":"Adv Psychiatry Ther"},{"issue":"4","key":"472_CR9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/schbul\/23.4.567","volume":"23","author":"TE Hansen","year":"1997","unstructured":"Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr Bull. 1997;23(4):567\u201382.","journal-title":"Schizophr Bull"},{"key":"472_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","volume":"7","author":"A \u00dc\u00e7ok","year":"2008","unstructured":"\u00dc\u00e7ok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008;7:58\u201362.","journal-title":"World Psychiatry"},{"key":"472_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.schres.2017.01.043","volume":"189","author":"M Cantillon","year":"2017","unstructured":"Cantillon M, Prakash A, Alexander A, et al. Dopamine serotonin stabilizer RP5063: a randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder. Schizophr Res. 2017;189:126\u201333.","journal-title":"Schizophr Res"},{"issue":"4","key":"472_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1517\/14728214.2014.958148","volume":"19","author":"LS Koeste","year":"2014","unstructured":"Koeste LS, Carbon M, Correll CU. Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs. 2014;19(4):511\u201331.","journal-title":"Expert Opin Emerg Drugs"},{"key":"472_CR13","doi-asserted-by":"publisher","first-page":"006622","DOI":"10.1002\/14651858.cd006622.pub2","volume":"8","author":"RB Belgamwar","year":"2011","unstructured":"Belgamwar RB, El-Sayeh HG. Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst Rev. 2011;8:006622. https:\/\/doi.org\/10.1002\/14651858.cd006622.pub2 (Review. PubMed PMID: 21833956.).","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl","key":"472_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2152\/jmi.52.284","volume":"52","author":"T Hirose","year":"2005","unstructured":"Hirose T, Kikuchi T. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Investig. 2005;52(suppl):284\u201390.","journal-title":"J Med Investig"},{"issue":"1","key":"472_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","volume":"333","author":"B Kiss","year":"2010","unstructured":"Kiss B, Horvath A, Nemethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3\/D2 dopamine receptor antagonist\u2013partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328\u201340.","journal-title":"J Pharmacol Exp Ther"},{"key":"472_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulators. J Pharmacol Exp Ther. 2014;350:589\u2013604.","journal-title":"J Pharmacol Exp Ther"},{"key":"472_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.bbr.2017.02.036","volume":"332","author":"L Rajagopal","year":"2017","unstructured":"Rajagopal L, Kwon S, Huang M, et al. RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia. Behav Brain Res. 2017;332:180\u201399.","journal-title":"Behav Brain Res"},{"key":"472_CR18","unstructured":"Bhat L, Adiey K, Seema R Bhat SR, et al. RP5063, a novel dopamine serotonin stabilizer, displays antipsychotic efficacy in rodents. Front Pharmacol. (Submitted)."},{"key":"472_CR19","first-page":"1","volume":"00","author":"M Cantillon","year":"2017","unstructured":"Cantillon M, Ings R, Bhat L. Pharmacokinetics of RP5063 following single doses to normal healthy volunteers and multiple doses over 10\u00a0days to stable schizophrenic patients. Clin Transl Sci. 2017;00:1\u20139.","journal-title":"Clin Transl Sci"},{"key":"472_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cts.12545","volume":"00","author":"M Cantillon","year":"2018","unstructured":"Cantillon M, Ings R, Bhat L. Initial clinical experience of RP5063 following single doses in normal healthy volunteers and multiple doses in patients with stable schizophrenia. Clin Transl Sci. 2018;00:1\u201310. https:\/\/doi.org\/10.1111\/cts.12545 .","journal-title":"Clin Transl Sci"},{"issue":"2","key":"472_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull"},{"key":"472_CR22","unstructured":"FDA Guidance: Guidance to Industry: bioanalytical method validation. Draft Guidance. September 2013. https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm368107.pdf . Accessed date 13 May 2017."},{"issue":"3","key":"472_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2307\/2532087","volume":"46","author":"MJ Lindstrom","year":"1990","unstructured":"Lindstrom MJ, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics. 1990;46(3):673\u201387.","journal-title":"Biometrics"},{"issue":"3","key":"472_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10928-006-9046-9","volume":"34","author":"C Dartois","year":"2007","unstructured":"Dartois C, Lemenuel-Diot A, Laveille C, et al. Evaluation of uncertainty parameters estimated by different population pharmacokinetic software and methods. J Pharmacokinet Pharmacodyn. 2007;34(3):289\u2013311.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"472_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1214\/ss\/1177011136","volume":"7","author":"A Gelman","year":"1992","unstructured":"Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7:457\u201372.","journal-title":"Stat Sci"},{"issue":"3","key":"472_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/cmb.2009.0179","volume":"17","author":"D Nicholas","year":"2010","unstructured":"Nicholas D, Pattengale D, Alipour M, et al. How many bootstrap replicates are necessary? J Comput Biol. 2010;17(3):337\u201354.","journal-title":"J Comput Biol"},{"key":"472_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/BF01061469","volume":"20","author":"JW Mandema","year":"1992","unstructured":"Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic\u2013pharmacodynamic models. J Pharmacokin Biopharm. 1992;20:511\u201328.","journal-title":"J Pharmacokin Biopharm"},{"key":"472_CR28","volume-title":"Generalized additive models","author":"TJ Hastie","year":"1990","unstructured":"Hastie TJ, Tibshirani RJ. Generalized additive models. New York: Chapman and Hall\/CRC; 1990."},{"issue":"3","key":"472_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10928-005-9002-0","volume":"33","author":"C Csajka","year":"2006","unstructured":"Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn. 2006;33(3):227\u201379.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"472_CR30","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1365-2125.2008.03223.x","volume":"66","author":"J Kim","year":"2008","unstructured":"Kim J, Seo HB, Cho JY, et al. Population pharmacokinetic modelling of aripiprazole and its metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol. 2008;66:802\u201310.","journal-title":"Br J Clin Pharmacol"},{"key":"472_CR31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2165\/11532580-000000000-00000","volume":"12","author":"ED Lobo","year":"2010","unstructured":"Lobo ED, Robertson-Plouch C, Quinlan T, et al. Oral olanzepine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model. Paediatr Drug. 2010;12:201\u201311.","journal-title":"Paediatr Drug"},{"issue":"1","key":"472_CR32","doi-asserted-by":"publisher","first-page":"16276","DOI":"10.1038\/s41598-017-16358-6","volume":"7","author":"S Yang","year":"2017","unstructured":"Yang S, Noh H, Hahn J, et al. Population pharmacokinetics of remifentanil in critically ill patients receiving extracorporeal membrane oxygen. Sci Rep. 2017;7(1):16276. https:\/\/doi.org\/10.1038\/s41598-017-16358-6 .","journal-title":"Sci Rep"},{"key":"472_CR33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1475-2875-8-200","volume":"8","author":"K Stepniewska","year":"2009","unstructured":"Stepniewska K, Taylor W, Sirima SB, et al. Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J. 2009;8:200. https:\/\/doi.org\/10.1186\/1475-2875-8-200 .","journal-title":"Malar J"},{"key":"472_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7243\/2050-120X-2-1","volume":"2","author":"T Frank","year":"2013","unstructured":"Frank T. Population pharmacokinetics of lixisenatide, a once-daily human glucagon-like peptide-1 receptor agonist, in healthy subjects and in patients with type 2 diabetes. J Pharm Drug Deliv Res. 2013;2:1. https:\/\/doi.org\/10.4172\/2325-9604.1000112 .","journal-title":"J Pharm Drug Deliv Res"},{"issue":"19","key":"472_CR35","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1200\/JCO.2002.01.005","volume":"20","author":"Ch Kesteren Van","year":"2002","unstructured":"Van Kesteren Ch, Math\u00f4t RA, Raymond E, et al. Population pharmacokinetics of the novel anticancer agent E7070 during 4 phase 1 studies: model building and validation. J Clin Oncol. 2002;20(19):4065\u201373.","journal-title":"J Clin Oncol"},{"issue":"6","key":"472_CR36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1365-2125.2008.03223.x","volume":"66","author":"JR Kim","year":"2008","unstructured":"Kim JR, Seo HB, Cho JY, et al. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole in psychiatric patients. Br J Clin Pharmacol. 2008;66(6):802\u201310.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"472_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2133\/dmpk.22.358","volume":"22","author":"M Kubo","year":"2007","unstructured":"Kubo M, Koue T, Maune H, et al. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet. 2007;22(5):358\u201366.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"472_CR38","doi-asserted-by":"publisher","first-page":"1000162","DOI":"10.4172\/2167-065X.1000162","volume":"5","author":"G Ayano","year":"2016","unstructured":"Ayano G. Psychotropic medications metabolized by cytochromes P450 (CYP) 2D6 enzyme and relevant drug interactions. Clin Pharmacol Biopharm. 2016;5(4):1000162. https:\/\/doi.org\/10.4172\/2167-065X.1000162 .","journal-title":"Clin Pharmacol Biopharm"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-018-0472-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0472-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0472-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T22:49:39Z","timestamp":1571006979000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-018-0472-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["472"],"URL":"https:\/\/doi.org\/10.1007\/s13318-018-0472-z","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,4]]},"assertion":[{"value":"4 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Reviva Pharmaceuticals, Inc. provided sponsorship funding for the REFRESH clinical trial and for a grant to Davide Verotta, PhD for population analysis, and for editorial development by Akita Biomedical, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Arul Prakash, M. Pharm., Laxminarayan Bhat, PhD, and Marc Cantillon, MD are employees of Reviva Pharmaceuticals, Inc., and Robert Ings, PhD is a consultant to Reviva Pharmaceuticals, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in the phase 2 REFRESH trial were in accordance with the 1964 Helsinki declaration (and its amendments). This study was approved by institutional review boards for each of the investigative sites located in India, Philippines, Malaysia, Moldova, and USA. Written informed consent was obtained from participants directly, or from parents or care givers of all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}